FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307922433> ?p ?o ?g. }

• W4307922433 endingPage "2395" @default.
• W4307922433 startingPage "2386" @default.
• W4307922433 abstract "Aims The interleukin-23 (IL-23) inhibitor risankizumab was recently approved for the treatment of moderate-to-severe plaque psoriasis in the United States. Low rates of cerebrovascular accident (CVA) were observed in risankizumab-treated patients during clinical trials. The aim of this study was to determine whether risankizumab may be associated with CVA in a real-world setting. Methods A retrospective disproportionality analysis was conducted utilizing postmarketing adverse event reports submitted to the US Food and Drug Administration Adverse Event Reporting System (FAERS) through the fourth quarter of 2021. A custom query consisting of 22 CVA-related Medical Dictionary for Regulatory Activities (MedDRA) preferred terms previously reported in clinical trials of plaque psoriasis medications was used to identify cases. Disproportionality was measured by calculating reporting odds ratios (ROR) and 95% confidence intervals (CI), whereby the lower limit of a 95% CI >1.0 and ≥ three cases was considered a signal. Results Risankizumab was associated with significantly disproportionate CVA reporting compared to all other drugs in FAERS (ROR 2.48; 95% CI 2.14–2.88) as well as 11 alternative plaque psoriasis therapeutics across five pharmacologic classes. The largest disproportionality signals for risankizumab were identified relative to apremilast (ROR 9.07; 95% CI 7.56–10.89), ixekizumab (ROR 6.75; 95% CI 5.14–8.86), guselkumab (ROR 6.74; 95% CI 4.68–9.71), certolizumab (ROR 5.70; 95% CI 4.74–6.85) and etanercept (ROR 4.91; 95% CI 4.21–5.73). Conclusion This study detected a previously unreported signal of disproportionate CVA reporting with the real-world use of risankizumab. Further long-term observational data will be necessary to better characterize this unconfirmed potential safety signal." @default.
• W4307922433 created "2022-11-06" @default.
• W4307922433 creator A5041558524 @default.
• W4307922433 date "2022-11-15" @default.
• W4307922433 modified "2023-09-25" @default.
• W4307922433 title "Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)" @default.
• W4307922433 cites W1524926404 @default.
• W4307922433 cites W1964184432 @default.
• W4307922433 cites W1978824248 @default.
• W4307922433 cites W1983168493 @default.
• W4307922433 cites W2003687140 @default.
• W4307922433 cites W2008716526 @default.
• W4307922433 cites W2026966397 @default.
• W4307922433 cites W2048174668 @default.
• W4307922433 cites W2056361036 @default.
• W4307922433 cites W2064716383 @default.
• W4307922433 cites W2066752983 @default.
• W4307922433 cites W2068525133 @default.
• W4307922433 cites W2071343804 @default.
• W4307922433 cites W2080390872 @default.
• W4307922433 cites W2099687194 @default.
• W4307922433 cites W2103120331 @default.
• W4307922433 cites W2113330592 @default.
• W4307922433 cites W2116098803 @default.
• W4307922433 cites W2124481557 @default.
• W4307922433 cites W2129056186 @default.
• W4307922433 cites W2131430597 @default.
• W4307922433 cites W2143786724 @default.
• W4307922433 cites W2255285771 @default.
• W4307922433 cites W2326643498 @default.
• W4307922433 cites W2517590517 @default.
• W4307922433 cites W2540989688 @default.
• W4307922433 cites W2551958233 @default.
• W4307922433 cites W2606035821 @default.
• W4307922433 cites W2606731929 @default.
• W4307922433 cites W2608364534 @default.
• W4307922433 cites W2752721387 @default.
• W4307922433 cites W2789922753 @default.
• W4307922433 cites W2793737891 @default.
• W4307922433 cites W2795704864 @default.
• W4307922433 cites W2896096472 @default.
• W4307922433 cites W2900015706 @default.
• W4307922433 cites W2914736751 @default.
• W4307922433 cites W2924833996 @default.
• W4307922433 cites W2943227877 @default.
• W4307922433 cites W2955086440 @default.
• W4307922433 cites W2985843002 @default.
• W4307922433 cites W3013516711 @default.
• W4307922433 cites W3014609838 @default.
• W4307922433 cites W3022784957 @default.
• W4307922433 cites W3034204123 @default.
• W4307922433 cites W3042689359 @default.
• W4307922433 cites W3082360571 @default.
• W4307922433 cites W3083864580 @default.
• W4307922433 cites W3122226502 @default.
• W4307922433 cites W3193337461 @default.
• W4307922433 cites W3196805922 @default.
• W4307922433 cites W4200349236 @default.
• W4307922433 cites W4210529991 @default.
• W4307922433 doi "https://doi.org/10.1111/bcp.15581" @default.
• W4307922433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36321844" @default.
• W4307922433 hasPublicationYear "2022" @default.
• W4307922433 type Work @default.
• W4307922433 citedByCount "6" @default.
• W4307922433 countsByYear W43079224332023 @default.
• W4307922433 crossrefType "journal-article" @default.
• W4307922433 hasAuthorship W4307922433A5041558524 @default.
• W4307922433 hasConcept C126322002 @default.
• W4307922433 hasConcept C156957248 @default.
• W4307922433 hasConcept C16005928 @default.
• W4307922433 hasConcept C197636746 @default.
• W4307922433 hasConcept C197934379 @default.
• W4307922433 hasConcept C199475168 @default.
• W4307922433 hasConcept C2777105317 @default.
• W4307922433 hasConcept C2780564577 @default.
• W4307922433 hasConcept C44249647 @default.
• W4307922433 hasConcept C57658597 @default.
• W4307922433 hasConcept C71924100 @default.
• W4307922433 hasConceptScore W4307922433C126322002 @default.
• W4307922433 hasConceptScore W4307922433C156957248 @default.
• W4307922433 hasConceptScore W4307922433C16005928 @default.
• W4307922433 hasConceptScore W4307922433C197636746 @default.
• W4307922433 hasConceptScore W4307922433C197934379 @default.
• W4307922433 hasConceptScore W4307922433C199475168 @default.
• W4307922433 hasConceptScore W4307922433C2777105317 @default.
• W4307922433 hasConceptScore W4307922433C2780564577 @default.
• W4307922433 hasConceptScore W4307922433C44249647 @default.
• W4307922433 hasConceptScore W4307922433C57658597 @default.
• W4307922433 hasConceptScore W4307922433C71924100 @default.
• W4307922433 hasIssue "8" @default.
• W4307922433 hasLocation W43079224331 @default.
• W4307922433 hasLocation W43079224332 @default.
• W4307922433 hasOpenAccess W4307922433 @default.
• W4307922433 hasPrimaryLocation W43079224331 @default.
• W4307922433 hasRelatedWork W1669499790 @default.
• W4307922433 hasRelatedWork W2555057678 @default.
• W4307922433 hasRelatedWork W2592450025 @default.
• W4307922433 hasRelatedWork W2755778884 @default.

• next